HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Raises Product Prices in US And Europe As Costs Rise

Executive Summary

GSK revealed price increases in the US, Europe and China as it posted Q3 sales up high single-digits, with gains in key categories such as pain relief and vitamins, minerals and supplements.

You may also be interested in...



Karo Pharma Adds VMS With Deal For Belgium's Sylphar

Sweden's Karo Pharma is acquiring Sylphar Group and its dietary supplement and beauty brands sold around Europe, primarily online.

AESGP Regulatory Conference: EU Pharma Strategy, Med Devices Regs, European Green Deal And GCSF Sustainability Charter Launch

HBW Insight reports on a packed agenda at the AESGP's Regulatory Conference on 25 November. Panels discuss the implications of raft of legislative changes for the European self-care industry, including the incoming EU Pharmaceutical Strategy, the new Medical Devices Regulations, and the inter-related European Green Deal, Farm to Fork and Chemicals Strategies. The conference also saw the launch of the GSCF's Charter for Environmentally Sustainable Self-Care.

Over The Counter 22 November 2021: CHC Spin Outs, Supply Chain Issues And Other Q3 Trends

In this episode, HBW Insight’s US and EU editors analyse Q3 OTC business trends, including why the biggest pharmaceutical companies in the world are spinning out their consumer health businesses to create new standalone firms and what's causing the supply chain troubles that are driving up OTC product prices.

Topics

UsernamePublicRestriction

Register

RS151890

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel